Caring for chronic kidney disease patients: focus on mineral and bone disorders.
This case study focuses on a patient with chronic kidney disease (CKD) with mineral and bone disorders (MBD) and the relationship and management strategies used in treating CKD-MBD. The various risks and issues pertaining to the CKD stage 5 patient population are addressed, including CKD-MBD and renal osteodystrophy. Proper management of CKD-MBD with diet, dialysis, laboratory testing, and medications is discussed. An interdisciplinary team that includes the patient and family is crucial for effective management of MBD.
Nguyen
Timothy V
TV
Nephrology and Dialysis, Holy Name Hospital, Department of Pharmacy, Teaneck, NJ 07666, USA. timnguyenpharmd@gmail.com
Filson
Jennifer
J
D002118:Calcium / Q000097:blood; D002614:Chelating Agents / Q000627:therapeutic use; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000209:etiology* / Q000628:therapy*; D000069449:Cinacalcet; D004035:Diet Therapy; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000628:therapy; D054559:Hyperphosphatemia / Q000628:therapy; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy; D008659:Metabolic Diseases / Q000209:etiology* / Q000628:therapy*; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use; D010281:Parathyroid Hormone / Q000097:blood; D010593:Pharmaceutical Services; D010758:Phosphorus / Q000097:blood; D044169:Receptors, Calcium-Sensing / Q000819:agonists; D006435:Renal Dialysis; D014807:Vitamin D / Q000819:agonists / Q000627:therapeutic use
D002614:Chelating Agents; D009281:Naphthalenes; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D014807:Vitamin D; D010758:Phosphorus; D002118:Calcium; D000069449:Cinacalcet